Polpharma Biologics is a fast-growing business that develops and manufactures biopharmaceuticals as new molecular entities (NMEs) or biosimilars, and also delivers biopharmaceutical CDMO services.
Building an integrated biosimilars business
- Published:
- written by: Polpharma Biologics
Related news
Other news related to this topic that may be of interest to you
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Rotkreuz – 31 July 2026 – Polpharma Biologics International AG today announces that the U.S. Food and...
Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus®...
Polpharma Biologics and PSI CRO Collaborate on Phase 1 Biosimilar Study in Multiple Sclerosis
June 03, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...
Polpharma Biologics and Tuteur sign a licensing agreement for a biosimilar targeting autoimmune diseases
May 22, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...